<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271776</url>
  </required_header>
  <id_info>
    <org_study_id>METC 143026</org_study_id>
    <nct_id>NCT02271776</nct_id>
  </id_info>
  <brief_title>GOS and Insulin Sensitivity</brief_title>
  <official_title>The Effects of Galactooligosaccharide (GOS) on Peripheral Insulin Sensitivity and Body Weight Control in Obese Adults With Impaired Glucose Homeostasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Top Institute Food and Nutrition</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on our hypothesis that orally administered GOS will be fermented into a SCFA pattern
      high in acetate and that this will lead to beneficial effects on human substrate and energy
      metabolism, we aim to address the following primary objective:

      To investigate the effects of a 12-week supplementation of GOS on peripheral insulin
      sensitivity and body weight control in obese adults with impaired glucose homeostasis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">October 2015</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>systemic insulin sensitivity</measure>
    <time_frame>change from baseline at 12 week supplementation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>substrate oxidation and energy expenditure</measure>
    <time_frame>change from baseline at 12 week supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma markers of substrate and energy metabolism</measure>
    <time_frame>change from baseline at week 1 and at 12 week supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal and plasma SCFA concentrations</measure>
    <time_frame>change from baseline at week 1 and at 12 week supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fecal microbiota composition</measure>
    <time_frame>change from baseline at week 1 and at 12 week supplementation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>skeletal muscle and adipose tissue gen and protein expression</measure>
    <time_frame>change from baseline at week 1 and at 12 week supplementation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Obesity</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Galactooligosaccharide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5g 3x per day for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>maltodextrin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3x per day for 12 weeks (isocaloric to intervention)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Galactooligosaccharide</intervention_name>
    <description>The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks</description>
    <arm_group_label>Galactooligosaccharide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>maltodextrin</intervention_name>
    <arm_group_label>maltodextrin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Overweight/obese (BMI ≥ 28 kg/m2 &lt; 40 kg/m2) insulin impaired men and post-menopausal women
        with impaired glucose tolerance (IGT: 2h plasma glucose during 75g OGTT 7.8-11.1 mmol/l)
        and/or impaired fasting glucose (plasma glucose ≥ 5.6 mmol/l) aged 45-70 years will be
        included in the study.

        In addition, subjects have to be weight-stable for at least 3 months prior to participation
        (no change in bodyweight, i.e. &lt; 3kg).

        Exclusion Criteria:

          -  diabetes mellitus

          -  gastroenterological diseases or major abdominal surgery (allowed i.e.: appendectomy,
             cholecystectomy)

          -  lactose intolerance and other digestive disorders

          -  cardiovascular disease, cancer, liver or kidney malfunction (determined based on ALAT
             and creatinine levels, respectively)

          -  disease with a life expectancy shorter than 5 years

          -  abuse of products (alcohol consumption &gt; 15 units/week, or any drugs)

          -  excessive nicotine use defined as &gt;20 cigarettes per day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ellen E Blaak</last_name>
    <role>Principal Investigator</role>
    <affiliation>MUMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Human Biology, Maastricht University Medical Centre</name>
      <address>
        <city>Maastricht</city>
        <zip>6200MD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin Sensitivity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

